PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | MicrobiomeTrials← Back to trialsNCT04477785
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
RecruitingOBSERVATIONAL
Trial Details
Start: 2020-07-01Est. Completion: 2033-12
Enrollment target: 4,500 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Mayo Foundation for Medical Education and Research, Scottsdale, Arizona, United States
- Banner Research Institute, Sun City, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- Keck School of Medicine of USC, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Institute For Neurodegenerative Disorders, New Haven, Connecticut, United States
- Parkinson's Disease& Movement Disorder Center of Boca Raton, Boca Raton, Florida, United States
- University of Florida, Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
Other microbiome trials you might be interested in
Idiopathic Parkinson´s DiseaseParkinson's Disease
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be i…
Tucson, United StatesEst. completion Sep 2027
Head and Neck Neoplasms
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in c…
La Jolla, United StatesEst. completion Jul 25, 2024
Johns Hopkins University, Baltimore, Maryland, United StatesBoston University, Boston, Massachusetts, United StatesMassachusetts General Hospital, Boston, Massachusetts, United StatesUniversity of Michigan, Ann Arbor, Michigan, United StatesCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United StatesBeth Israel Medical Center, New York, New York, United StatesNYU Langone Health, New York, New York, United StatesUniversity of Rochester, Rochester, New York, United StatesUniversity of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio, United StatesCleveland Clinic, Cleveland, Ohio, United StatesOregon Health &Science University, Portland, Oregon, United StatesUniversity of Pennsylvania, Philadelphia, Pennsylvania, United StatesUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United StatesBaylor College of Medicine, Houston, Texas, United StatesUniv of Washington and VA Puget Sound Health Care System, Seattle, Washington, United StatesInnsbruck Medical University, Innsbruck, AustriaThe Ottawa Hospital - Civic Campus, Ottawa, Ontario, CanadaToronto Western Hospital, Toronto, Ontario, CanadaMcGill University, Montreal, Quebec, CanadaPhilipps-University of Marburg, Hessen, GermanyParacelsus-Elena Klinik, Kassel, GermanyUniversity of Luebeck, Lübeck, GermanyUniversity of Tuebingen, Tübingen, GermanyFoundation for Biomedical Research of the Academy of Athens, Athens, Athens, GreeceTel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, IsraelUniversity of Salerno, Salerno, Salerno, ItalyParkinson Research Clinic, Luxembourg, LuxembourgRadboud University, Nijmegen, Gelderland, NetherlandsLagos College of Medicine, University of Lagos, Lagos, Lagos, NigeriaHospital Clinic de Barcelona, Barcelona, Barcelona, SpainHospital Donostia, Donostia / San Sebastian, San Sebastian, SpainQueen Mary University of London, London, Britain, United KingdomNewcastle University, Newcastle upon Tyne, Tyne and Wear, United KingdomImperial College London, London, United KingdomJohn Radcliffe Hospital Oxford and Oxford University, Oxford, United KingdomCarcinoma, Non-Small-Cell Lung
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-…
Gilbert, United StatesEst. completion May 16, 2033